The net worth of the market share of the anti-biofilm wound dressing is predicted to reach from US$ 782.60 million in 2023 to over US$ 1939.45 million by 2033, recording a CAGR of 9.5% between 2023 and 2033. Incidence rates for chronic and acute wounds are expected to increase which is, driving demand for anti-biofilm wound dressings.
Besides antimicrobial resistance and unhealthy sedentary lifestyles, tobacco and alcohol consumption contribute to the rising non-communicable disease burden. This is because chronic diseases such as diabetes, cancer, and other autoimmune diseases become more prevalent.
Request a Sample Report with Table of Content (ToC) @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16474
There are also several other factors contributing to the market’s growth, including the development of healthcare infrastructure across developing countries, and technological advancements in wound management. The efforts made by healthcare providers and key players to make wound care more popular.
“Telehealth has played a key role in the strong recovery of the wound care market. Various healthcare providers have developed telehealth platforms to effectively manage patients with chronic and acute wounds.” says a lead analyst at Future Market Insights.
Key Takeaways from Market Study
- The market for anti-biofilm wound dressing is expected to record a CAGR of 9.5% over the forecast period.
- According to estimates, the anti-biofilm wound dressing market in North America may remain strong throughout the length of the forecast period.
- Acute wound segment dominated the market and is expected to record a CAGR of 9.3%.
Ask An Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16474
Competitive Landscape:
Several prominent companies dominate this market, including ConvaTec, Smith & Nephew PLC, Urgo Medical, Coloplast, and 3M.
Anti-biofilm wound dressing has developed significantly in the industry through partnerships, acquisitions, and research and development. These strategies have resulted in major developments.
Recent Developments:
- Convatec Inc. acquired Triad Life Sciences Inc. in March 2022 for US$ 450 million. This acquisition was made with the aim of strengthening its portfolio of biomedical products for surgical wounds and chronic wounds.
- The FDA cleared an antimicrobial matrix product made by Imbed Biosciences, Microlyte Matrix, in April 2021. The product can be used to treat surgical, traumatic, and chronic wounds.
- For the treatment of diabetic foot ulcers, pressure ulcers, leg ulcers, and dehisced surgical wounds, ConvaTec Group Plc (ConvaTec) launched a new medication called “ConvaMax” in January 2020. As well as adhesion-free options, the product is also available in non-adhesive forms, allowing for total flexibility when it comes to integrating compression bands and other main dressings.
- In January 2018, Imbed Biosciences introduced the market with Microlyte Ag after raising over US$ 1.6 million to research silver-based anti-biofilm wound dressings.
- As a result of this acquisition, Smith & Nephew PLC expanded its product portfolio for advanced wound management, increasing its market share and customer base. In April 2019, the company acquired Osiris Therapeutics, Inc., a regenerative medicine company. As a result of this acquisition, the company will boost its growth by expanding its product portfolio for advanced wound management.
Request Discount@ https://www.futuremarketinsights.com/request-discount/rep-gb-16474
Anti-biofilm Wound Dressing Market Segmentation by Category
By Mode of Mechanism:
- Physical
- Chemical
- Biological
By Wound Type:
- Chronic Wounds
- Acute Wounds
By End User:
- Hospitals and Clinics
- Surgical Centers
- Other End users
About FMI:
Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.
Contact:
Unit No: 1602-006
Jumeirah Bay 2
Plot No: JLT-PH2-X2A
Jumeirah Lakes Towers
Dubai
United Arab Emirates
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs
